OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab
OP21 研究表明，接受英夫利昔单抗、乌司奴单抗或托法替尼治疗的炎症性肠病患者，其新冠疫苗诱导的抗体反应受损；而接受硫嘌呤类药物或维多珠单抗治疗的患者，其抗体反应则不受影响。
期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjab197
Verburgt, Charlotte M; Dunn, Katherine A; Van Limbergen, Johan E; Alexander, J; Kennedy, N; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Castro Seoane, R; Liu, Z; Nice, R; Bewshea, C; D’Mello, A; Constable, L; Jones, G R; Balarajah, S; Fiorentino, F; Sebastian, S; Irving, P M; Hicks, L; Williams, H; Kent, A; Linger, R; King, R; Parkes, M; Kok, K; Patel, K; Altmann, D; Boyton, R; Goodhand, J; Hart, A; Lees, C; Ahmad, T; Powell, N
